Your browser doesn't support javascript.
loading
COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir.
Epling, Brian P; Rocco, Joseph M; Boswell, Kristin L; Laidlaw, Elizabeth; Galindo, Frances; Kellogg, Anela; Das, Sanchita; Roder, Allison; Ghedin, Elodie; Kreitman, Allie; Dewar, Robin L; Kelly, Sophie E M; Kalish, Heather; Rehman, Tauseef; Highbarger, Jeroen; Rupert, Adam; Kocher, Gregory; Holbrook, Michael R; Lisco, Andrea; Manion, Maura; Koup, Richard A; Sereti, Irini.
Afiliación
  • Epling BP; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Rocco JM; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Boswell KL; Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Laidlaw E; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Galindo F; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Kellogg A; Clinical Research Directorate (CRD), Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, MD, USA.
  • Das S; Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
  • Roder A; Systems Genomics Section, Laboratory of Parasitic Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Ghedin E; Systems Genomics Section, Laboratory of Parasitic Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Kreitman A; Systems Genomics Section, Laboratory of Parasitic Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Dewar RL; Virus Isolation and Serology Laboratory, Frederick National Laboratory, Frederick, MD, USA.
  • Kelly SEM; Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA.
  • Kalish H; Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA.
  • Rehman T; Virus Isolation and Serology Laboratory, Frederick National Laboratory, Frederick, MD, USA.
  • Highbarger J; Virus Isolation and Serology Laboratory, Frederick National Laboratory, Frederick, MD, USA.
  • Rupert A; AIDS Monitoring Laboratory, Frederick National Laboratory, Frederick, MD, USA.
  • Kocher G; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, USA.
  • Holbrook MR; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, USA.
  • Lisco A; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Manion M; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Koup RA; Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Sereti I; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
medRxiv ; 2022 Jun 17.
Article en En | MEDLINE | ID: mdl-35734093
Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported. We performed clinical, virologic, and immune measurements in seven patients with symptomatic rebound, six after nirmatrelvir/ritonavir treatment and one without previous treatment. There was no evidence of severe disease or impaired antibody and T-cell responses in people with rebound symptoms.
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: MedRxiv Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: MedRxiv Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos